» Authors » Satoshi Hirase

Satoshi Hirase

Explore the profile of Satoshi Hirase including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 100
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Ishimori S, Fujimura J, Nakanishi K, Hattori K, Hirase S, Matsunoshita N, et al.
Sci Rep . 2024 Aug; 14(1):19344. PMID: 39164342
There are currently no available data on the relationship between sonographic temporary nephromegaly in children during their first febrile urinary tract infection (fUTI) and recurrent fUTI. For this analysis, a...
2.
Hirase S, Takeo N, Nakamura M, Sato N, Matsunaga K, Taniguchi H, et al.
Arerugi . 2020 Feb; 69(1):48-52. PMID: 32051369
Background: Cochineal dyes are used as additives in various foods for the purpose of red coloration. On the other hand, although it has been reported as a causative agent of...
3.
Hirase S, Okafuji I, Kasai K, Matsumoto K, Tanaka Y, Tanaka Y, et al.
Pediatr Int . 2019 Jul; 61(9):847-851. PMID: 31264304
Background: Securing food for patients with food allergies may be more difficult during disasters, but reports on the status of household allergen-free food reserves in preparation for disasters are limited....
4.
Hasegawa D, Saito A, Nino N, Uemura S, Takafuji S, Yokoi T, et al.
J Pediatr Hematol Oncol . 2017 May; 40(1):e41-e44. PMID: 28538511
We herein reported a 4-month-old boy with transplantation-associated atypical hemolytic uremic syndrome (TA-aHUS) who was successfully treated with eculizumab. The patient diagnosed with type 3 of familial hemophagocytic lymphohistiocytosis underwent...
5.
Hirase S, Saitoh A, Hartomo T, Kozaki A, Yanai T, Hasegawa D, et al.
Oncol Lett . 2016 Jul; 12(2):1119-1123. PMID: 27446404
Neuroblastoma is an aggressive pediatric tumor accounting for ~15% of cancer-associated mortalities in children. Despite the current intensive therapy, >50% of high-risk patients experience tumor relapse or regrowth caused by...
6.
Yamamoto N, Kozaki A, Hartomo T, Yanai T, Hasegawa D, Kawasaki K, et al.
Oncol Lett . 2016 Jan; 10(5):3228-3232. PMID: 26722317
Neuroblastoma is an aggressive solid tumor that leads to tumor relapse in more than half of high-risk patients. Minimal residual disease (MRD) is primarily responsible for tumor relapses and may...
7.
Hirase S, Hasegawa D, Takahashi H, Moriwaki K, Saito A, Kozaki A, et al.
Int J Hematol . 2015 Oct; 102(5):594-601. PMID: 26440971
Recent studies have reported that the absolute lymphocyte count (ALC) during induction therapy is predictive of treatment outcome in de novo acute lymphoblastic leukemia (ALL); however, the significance of ALC...
8.
Hartomo T, Pham T, Yamamoto N, Hirase S, Hasegawa D, Kosaka Y, et al.
Int J Oncol . 2014 Dec; 46(3):1089-98. PMID: 25524880
Despite the introduction of 13-cis-retinoic acid (13-cis-RA) into the current chemotherapy, more than half of high-risk neuroblastoma patients have experienced tumor relapses driven by chemoresistant cancer stem cells (CSCs) that...
9.
Kubokawa I, Yachie A, Hayakawa A, Hirase S, Yamamoto N, Mori T, et al.
BMC Pediatr . 2014 Jun; 14:139. PMID: 24890946
Background: TAFRO syndrome is a unique clinicopathologic variant of multicentric Castleman's disease that has recently been identified in Japan. It is characterized by a constellation of symptoms: Thrombocytopenia, Anasarca, reticulin...
10.
Yamamoto N, Nishimura N, Takeuchi M, Ito T, Yokozaki H, Hirase S, et al.
Eur J Pediatr . 2013 Oct; 173(12):1615-8. PMID: 24169729
Post-transplant lymphoproliferative disorder (PTLD) is a well-recognized aggressive disease commonly associated with Epstein-Barr virus (EBV) infection after hematopoietic stem cell transplantation (HSCT). Although rituximab (RTX) is incorporated into the first-line...